Introduction: Sleep disturbances are common non-motor symptoms in Parkinson's disease (PD). Experimental studies suggest involvement of the serotonergic system in the regulation of sleep and arousal. Using [ 11 C]DASB positron emission tomography, a marker of serotonin transporter availability, we investigated whether sleep dysfunction is associated with serotonergic dysfunction in PD.
Introduction
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterised by the cardinal motor symptoms of bradykinesia, rigidity and tremor, and a range of frequent nonmotor symptoms such as sleep disturbances, depression and chronic fatigue. Sleep disturbances are estimated to affect between 15-96% of patients with PD, constituting a significant source of complaint and affecting quality of life 1, 2 . Sleep disturbances in PD are typically divided to insomnia, parasomnias including rapid eye movement (REM) behaviours A C C E P T E D M A N U S C R I P T 4 involved in the regulation of sleep, wakefulness and arousal including the forebrain, hypothalamus, thalamus, basal ganglia and preoptic area 6 .
Post-mortem studies revealed up to 50% loss of serotonergic neurons in the brains of patients with PD 7 . Biochemical studies confirmed these findings demonstrating decreased levels of serotonin transporter (SERT) protein in striatal and extra-striatal areas 8, 9 . Positron emission tomography (PET) molecular imaging studies measuring SERT availability have revealed reductions of striatal and extra-striatal 5-HT including raphe nuclei, thalamus and hypothalamus [10] [11] [12] . Furthermore, PET studies have linked serotonergic dysfunction with the development of dyskinesias 13 , tremor 14 , depression 15 , apathy and anxiety 16 , fatigue 17 , weight loss 18 and visual hallucinations 19 in PD. Therefore, there is compelling evidence from preclinical, post-mortem and human imaging studies for the role of serotonergic dysfunction in PD.
The serotonergic system plays a critical role in the sleep-wake cycle and its dysfunction could have relevance to the development of sleep disturbances in PD. Animal studies have demonstrated that lesions in the raphe nucleus result in reduced sleep which is associated with lower levels of serotonin 20 . Changes in raphe nuclei following sleep deprivation included increases in neuronal size, increased firing during wake and downregulation of 5-HT receptors 21 . Preclinical PET studies with [ 11 C]DASB demonstrated decreases in SERT binding in rats deprived of sleep 21 . Furthermore, PET studies in patients with PD have revealed reductions in SERT availability in key brain regions involved in the regulation of sleep and wakefulness 12 .
In this study, we hypothesized that PD patients with sleep dysfunction, as clinically identified using the original version of Parkinson Disease Sleep Scale (PDSS) 22 , would show reduced serotonergic function in brain areas modulating sleep and arousal. The PDSS is widely
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A C C E P T E D M A N U S C R I P T 5 validated and recommended by the MDS task force for clinical assessment of a range of sleep disorders and severity in PD 23 . We sought to investigate this in vivo using [ 11 C]DASB PET molecular imaging, as a marker of SERT availability.
Material and methods

Participants
Patient selection was carried out from a cohort of 56 patients with a clinical diagnosis of idiopathic PD (Figure 1) 
Scanning procedures
Participants were scanned using a GE Discovery RX PET/CT scanner. The mean injected Axial FLAIR: TR=9000ms, TE=114ms, TI=2500ms, 5mm slice thickness).
[ 11 C]DASB PET analysis
Individual PET frames were corrected for head motion using frame-by-frame realignment using a frame with high signal-to-noise ratio as reference. Summed dynamic [ 11 C]DASB images were created from the entire series of uptake image volumes. Parametric images of [ 11 C]DASB distribution volume ratios (DVR) were generated using the Logan reference model with reference region for non-specific tracer-binding signal in the posterior cerebellar grey matter cortex avoiding inclusion of the vermis 25 . Regional concentrations of radioactivity (kBq/ml) were obtained from the full dynamic scan and decay-corrected timeactivity curves (TACs) were computed. PET images were anatomically co-registered and resliced to the corresponding T1-weighted MRI using the mutual information registration algorithm in the statistical parametric mapping (SPM) software package (Version 12).
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Manual delineation of ROIs was performed on co-registered MRI and PET using ANALYZE medical imaging software (version 12, Mayo Foundation). ROIs were manually defined on both hemispheres for the caudate, putamen, ventral striatum, amygdala, thalamus, hypothalamus, globus pallidus, raphe nucleus, anterior cingulate cortex, posterior cingulate cortex, prefrontal cortex and insula. The binding potential of the specially bound radioligand relative to the non-displaceable radioligand (BP ND ) in the tissue was calculated as DVR-1 26 .
Since changes in BP ND could be associated with degeneration or volumetric loss, we confirmed there were no differences in grey matter volumes on individual subjects MRIs between groups of PD patients with and without sleep disturbances and healthy controls; therefore, partial volume correction was not applied.
Statistical analysis
Statistical analysis and graph illustration were performed with SPSS (version 20 Chicago, Illinois, USA) and GraphPad Prism (version 6.0) respectively. For all variables, variance homogeneity and Gaussianity were tested with Barrlett and Kolmogorov-Smirnov tests, and
we proceeded with parametric tests as our PET and clinical data were normally distributed.
Regional 
Results
Clinical measures between the two groups of patients with PD revealed no significant differences in age (P>0.10; r=0. 12 Figure 2 ). There were no volumetric differences in any regions of interest between the groups of patients with PD and healthy controls (P>0.10) (Supplemental Data: Table e-1).
Correlations
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A C C E P T E D M A N U S C R I P T r=0.90) and raphe nuclei (P<0.001; r=0.83) in all 28 patients with PD ( Figure 4 ).
Discussion
Our findings demonstrate that sleep dysfunction in PD is associated with reduced serotonergic function in the midbrain raphe, basal ganglia and hypothalamus. Using a highlighted the role of the glymphatic system in the removal of potentially neurotoxic protein waste, which accumulates during wakefulness, from the brain at a highest rate during sleep 44 .
Dysregulation of the glymphatic system, potentially due to sleep dysfunction, could result in abnormal accumulation of protein aggregates such as alpha-synuclein and beta-amyloid 45 . Acknowledgements: We thank all the participants who kindly agreed to take part in this study. 
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